CA Medical - Page 5
Home CA Medical
California Medical News - including research, biotech, medical services and related
Northern California Physician Incorporates His Personal Experience Into an Individualized Treatment Approach for Optimizing Fertility
SACRAMENTO, Calif. -- 7.3 million women experience infertility each year in the U.S. alone. In fact, 1 in 5 women have difficulty conceiving as more women than ever are having their first or subsequent child after the age of 35, a contributing factor of infertility. Enter Dr. Robert Greene's forthcoming book, "PERFECT HORMONE BALANCE FOR FERTILITY: The Ultimate Guide to Getting Pregnant" (ISBN: 978-0-307-33740-5).
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity.
Cypress Systems, Inc. Launches Cancer Prevention Health Campaign
![cnw08-0415cypress Cypress Systems](http://californianewswire.com/CALIF/cnw08-0415cypress-150x150.jpg)
Mark Whitacre, Ph.D. Promoted to COO at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him
![Mark E. Whitacre, Ph.D.](http://californianewswire.com/CALIF/08-0325-mwhitacre_72dpi.thumbnail.jpg)
Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
![Epeius Biotechnologies](http://californianewswire.com/CALIF/08-0325-epeius_72dpi.thumbnail.jpg)
MedSort Online Health Record System Ensures Patient Privacy and Physician Efficiency
ENCINO, Calif. -- In December 2007, MedSort.com, a premier online personal medication list management system, launched a comprehensive personal health records system - MedSort Health(TM) - which empowers consumers and patients to take control of their health records. Since January 2007, MedSort.com has been helping patients to create and manage their medication and allergy list online.
As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.
San Diego Office Added by Always Best Care Senior Services
SAN DIEGO, Calif. -- Always Best Care Senior Services has expanded into the San Diego area. America's premier In-Home Care, Assisted Living Placement Service, and Personal Response Company, is proud to announce seniors in San Diego can now rely on Always Best Care Senior Services for outstanding care.
Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference...
SAN MARINO, Calif. and BOSTON, Mass. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA.
Sunshine Media, Inc. Announces M.D. News Magazine to the Inland Empire Marketplace
RIVERSIDE, Calif. -- Sunshine Media Inc. a leading publisher of locally focused business-to-business magazines covering high impact sectors of the economies of the United States and Canada, has named Bobby Thompson, Publisher of M.D. News, Inland Empire Region.
New Treatments for Kidney Cancer Offer Hope, but Create Difficult Choices for Cancer Patients
![California Kidney Cancer Foundation](http://californianewswire.com/CALIF/07-0907-cakidney_72dpi.thumbnail.jpg)
Renowned Fertility and Hormonal Health Expert Dr. Robert Greene to Lead Sacramento Reproductive Practice
SACRAMENTO, Calif. -- The Sher Institute for Reproductive Medicine - Sacramento (SIRM-Sacramento) has announced that Dr. Robert Greene will join as full-time medical director, operating out of the Sacramento headquarters as well as the Pleasanton and newly-established Redding satellite offices.
California Biotech Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Osmetech Licenses Roche Hot Start® Polymerase Technology
PASADENA, Calif. -- Osmetech plc (AIM; LSE: OMH) today announced that it has been granted a non-exclusive worldwide diagnostics license from Swiss-based F. Hoffman LaRoche Ltd and its US affiliate Roche Molecular Systems Inc. (collectively "Roche") to use Hot Start(R) polymerase technology in Osmetech nucleic acid diagnostic assays.
Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
![Epeius Biotechnologies](http://californianewswire.com/CALIF/07-0515-epeiusbio.thumbnail.jpg)
Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at C21 BioVentures Conference
![Epeius Biotechnologies](http://californianewswire.com/CALIF/07-0515-epeiusbio.thumbnail.jpg)
Tehachapi Hospital Foundation Seeks Funds to Save Rural Critical Access Facility
![Tehachapi Hospital](http://californianewswire.com/CALIF/07-0418-tehachhos_72dpi.thumbnail.jpg)
DermHair Clinic Provides New Hope and Applies New Technique for Baldness
![DermHair Clinic](http://californianewswire.com/CALIF/cnw-dermhair.thumbnail.jpg)
Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.
Rexin-G, The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies recently announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.